01
Beyond 10 mL?
With 70% of HCPs showing preference for subcutaneous formats, how might rising dose, concentration and viscosity push delivery architectures beyond conventional injection formats?
The context
Why delivery architecture matters
The global biologics market is estimated to expand from approximately $441 billion in early 2026 to $794 billion by 2030 and $1.1 trillion by 2035. As antibodies, proteins and peptides advance, delivery architecture is becoming a distinct area of scientific and commercial investigation.
From Rice’s year-long biologic delivery implant to Princeton spinout Optimeos’ targeted nanomedicine platform, universities and startups are researching hydrogels, nanoparticles, implantable systems and programmable delivery platforms to identify controllable formats for biologic release.
This webinar examines how the combination of route, architecture, material and release mechanism could determine biologic exposure, molecular stability, treatment duration and commercial potential. Assess which approaches offer a credible path from emerging research to next-generation delivery platforms.
What attendees will take away
- How dose, concentration and viscosity influence subcutaneous delivery design.
- Where microneedles, patches and tissue-based delivery may scale.
- How externally triggered and biologically responsive release systems differ.
- Which implant architectures could sustain exposure for months.
- How treatment duration may influence payer assessment.
- How to evaluate technology bets for 2030–2035.
The agenda
6 themes shaping biologic delivery architecture
02
Microneedles as a new route for biologics?
With 138 clinical-trial records identified, could microneedles, patches and tissue-based delivery systems become scalable platforms for biologics by 2030–2035?
03
Could programmable release become the norm?
Can biologic delivery move from predetermined release profiles toward externally triggered or biologically responsive systems by 2035?
04
Could implants replace repeated administration?
Which delivery architectures could extend biologic exposure from weeks toward months while preserving molecular stability and predictable release?
05
Delivery architecture, treatment duration and reimbursement
Could delivery architecture increasingly determine treatment duration and, in turn, how payers assess therapeutic value, cost-effectiveness and reimbursement?
06
Where will the 2030–2035 technology bets emerge?
Which combinations of route, architecture, material and release mechanism offer the strongest balance of therapeutic utility, technical feasibility and commercial potential?
The experts
Meet the speakers
Speaker
Arpit Sharma
Business Leader – Medical Devices & Diagnostics
Arpit Sharma brings extensive experience in global research, with insights into innovation, technology, market trends and competitive landscapes. With over 400 research assignments for MedTech clients, his expertise spans complex data analysis and strategic insights.
He supports knowledge management and data-driven CXO decisions, bridging university research and industry to help organizations and students become future-ready.
Host
Sandhya Saraswat
Manager – Medical Devices & Diagnostics
Sandhya Saraswat is a Manager – Healthcare Innovation Strategy at Stellarix, with over a decade of experience in MedTech, biotechnology, diagnostics and consumer healthcare. She specializes in technology consulting, startup and technology scouting, competitive intelligence, portfolio management and IP analytics.
Sandhya helps organizations translate emerging technologies into actionable insights, guide strategic initiatives and optimize innovation portfolios.
Assess the next biologic delivery architectures
Discover how next-generation delivery architectures are advancing biologics beyond conventional injections and reshaping the future of controlled, targeted, and programmable drug delivery.